Stage IV cancer is often treated as a single category, but clinically it is a spectrum. Some patients benefit from surgery; many do not. The central task is to identify when surgery changes the outcome curve and when it simply adds burden.
Stage IV is not one state: three practical scenarios
1. Potentially resectable metastatic disease -- There are cases where complete treatment of all visible disease is feasible. In selected cancers, this can produce durable control.
2. Oligometastatic disease -- A limited number of metastases where all sites are treatable with definitive local therapy. The key is biology and sequencing.
3. Diffuse metastatic disease -- Disease is widespread or biologically aggressive. Here, surgery is primarily palliative.
Two legitimate intents for surgery in stage IV
A. Long-term control / potential cure (selected cases) -- This requires a realistic pathway to treat all clinically relevant disease sites with acceptable morbidity.
B. Symptom relief / quality of life -- Examples include obstruction, uncontrolled bleeding, perforation risk, severe pain, or functional collapse.
Red flags against major surgery
- Rapid progression on first-line therapy
- Poor functional reserve
- Widespread multi-organ metastases without a clear local problem
- Vague intent ("maybe it helps")
Stage IV surgery is neither forbidden nor automatically beneficial. It is a precision decision: intent, biology, feasibility, and patient reserve determine whether the operation is rational or harmful.